The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Use of Nanovesicles from Orange Juice to Reverse Diet-Induced Gut Modifications in Diet-Induced Obese Mice
Open accessAbstract
We have determined whether orange juice-derived nanovesicles (ONVs) could be used for the treatment of obesity-associated intestinal complications. ONVs were characterized by lipidomic, metabolomic, electron microscopy. In vitro , intestinal barriers (IBs = Caco-2+HT-29-MTX) were treated with ONVs and co-cultured with adipocytes to monitor IB fat release. In vivo , obesity was induced with a high-fat, high-sucrose diet (HFHSD mice) for 12 weeks. Then, half of HFHSD mice were gavaged with ONVs. One-month ONV treatment did not modify HFHSD-induced insulin resistance but reversed diet-induced gut modifications. In the jejunum, ONVs increased villi size, reduced triglyceride content, and modulated mRNA levels of genes involved in immune response (tumor necrosis factor [TNF]-α and interleukin [IL]-1β), barrier permeability (CLDN1, OCLN, ZO1), fat absorption, and chylomicron release. ONVs targeted microsomal triglyceride transfer protein (MTP) and angiopoietin-like protein-4 (ANGPTL4), two therapeutic targets to reduce plasma lipids and inflammation in gastrointestinal diseases. Interestingly, ONV treatment did not aggravate liver steatosis, as MTP mRNA was increased in the liver. Therefore, ONVs protected both intestine and the liver from fat overload associated with the HFHSD. As ONVs concentrated amino acids and bioactive lipids versus orange juice, which are deficient in obese patients, the use of ONVs as a dietary supplement could bring physiological relevant compounds in the jejunum to accelerate the restoration of intestinal functions during weight loss in obese patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Filipe, V., Hawe, A., & Jiskoot, W. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0073-2 · Cited by 1,885 · cited 1×
“Particle Size and Surface Charge Analysis NanoSight NS300 (Malvern Panalytical, Orsay, France) was used to measure the size of particles.(49) The number of particles and their movement were recorded for 5 60 s (camera level = 16).”
Intestinal permeability – a new target for disease prevention and therapy
Bischoff, S. C., Barbara, G., Buurman, W., Ockhuizen, T., Schulzke, J.-D., Serino, M., Tilg, H., Watson, A., & Wells, J. M. (2014) · BMC Gastroenterology · doi:10.1186/s12876-014-0189-7 · Cited by 1,755 · cited 1×
“29,34 Conversely to what is observed for highly in fl ammatory pathologies (i.e., acute colitis or Crohn ’ s disease), chronic consumption of a high-fat diet turns off the immune response of the small intestine.”
Wiklander, O. P. B., Nordin, J. Z., O'Loughlin, A., Gustafsson, Y., Corso, G., Mäger, I., Vader, P., Lee, Y., Sork, H., Seow, Y., et al. (2015) · Journal of Extracellular Vesicles · doi:10.3402/jev.v4.26316 · Cited by 1,730
Self-citationPhosphatidic Acid-Mediated Mitogenic Activation of mTOR Signaling
Fang, Y., Vilella-Bach, M., Bachmann, R., Flanigan, A., & Chen, J. (2001) · Science · doi:10.1126/science.1066015 · Cited by 1,055
Plant-derived exosomal MicroRNAs shape the gut microbiota
Teng, Y., Ren, Y., Sayed, M., Hu, X., Lei, C., Kumar, A., Hutchins, E., Mu, J., Deng, Z., Luo, C., et al. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2018.10.001 · Cited by 1,027
Bonnard, C., Durand, A., Peyrol, S., Chanseaume, E., Chauvin, M.-A., Morio, B., Vidal, H., & Rieusset, J. (2008) · Journal of Clinical Investigation · doi:10.1172/jci32601 · Cited by 819
Self-citationSignaling functions of phosphatidic acid
WANG, X., DEVAIAH, S., ZHANG, W., & WELTI, R. (2006) · Progress in Lipid Research · doi:10.1016/j.plipres.2006.01.005 · Cited by 757
Morand, C., Dubray, C., Milenkovic, D., Lioger, D., Martin, J. F., Scalbert, A., & Mazur, A. (2011) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.110.004945 · Cited by 439
Plant derived edible nanoparticles as a new therapeutic approach against diseases
Zhang, M., Viennois, E., Xu, C., & Merlin, D. (2016) · Tissue Barriers · doi:10.1080/21688370.2015.1134415 · Cited by 311
Angptl4 serves as an endogenous inhibitor of intestinal lipid digestion
Mattijssen, F., Alex, S., Swarts, H. J., Groen, A. K., van Schothorst, E. M., & Kersten, S. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2013.11.004 · Cited by 88
Cited by
Lian, M. Q., Chng, W. H., Liang, J., Yeo, H. Q., Lee, C. K., Belaid, M., Tollemeto, M., Wacker, M. G., Czarny, B., & Pastorin, G. (2022) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12283 · Cited by 388
Plant‐Derived Vesicle‐Like Nanoparticles as Promising Biotherapeutic Tools: Present and Future
Feng, J., Xiu, Q., Huang, Y., Troyer, Z., Li, B., & Zheng, L. (2023) · Advanced Materials · doi:10.1002/adma.202207826 · Cited by 302
Plant-Derived Exosome-Like Nanovesicles: Current Progress and Prospects
Mu, N., Li, J., Zeng, L., You, J., Li, R., Qin, A., Liu, X., Yan, F., & Zhou, Z. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s420748 · Cited by 265
Plant-Derived Nanovesicles: Further Exploration of Biomedical Function and Application Potential
Li, A., Li, D., Gu, Y., Liu, R., Tang, X., Zhao, Y., Qi, F., Wei, J., & Liu, J. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.12.022 · Cited by 137
Metadata
- Authors
- Berger, E., Colosetti, P., Jalabert, A., Meugnier, E., Wiklander, O. P. B., Jouhet, J., Errazurig-Cerda, E., Chanon, S., Gupta, D., Rautureau, G. J. P., Geloen, A., El-Andaloussi, S., Panthu, B., Rieusset, J., & Rome, S.
- Venue
- Molecular Therapy - Methods & Clinical Development
- Publisher
- Elsevier BV
- Published
- 2020-09
- Volume
- 18
- Pages
- 880-892
- ISSN
- 2329-0501 (ISSN-L)
- OpenAlex
- W3049200396
- Cited by
- 159
- References
- 10
- FWCI
- 3.73
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.